| 货号 | 9002768-1mg |
| 描述 | Abiraterone is the active metabolite of abiraterone acetate (Item No. 15148). Abiraterone blocks cytochrome P450 17A1 (also known as steroid 17α-hydroxylase/17,20 lyase) by potently inhibiting both the 17α-hydroxylase and the 17,20 lyase activities (IC50 = 18 and 17 nM, respectively).1,2 In mice as well as men, it essentially eliminates plasma testosterone while producing a 3- to 4-fold increase in plasma luteinizing hormone.1,3 In clinical trials, abiraterone improves radiographic progression-free survival and significantly delays decline in human metastatic castration-resistant prostate cancer.4 |
| 别名 | CB-7598; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Barrie, S.E.,Potter, G.A.,Goddard, P.M., et al. Pharmacology of novel steroidal inhibitors of cytochrome P45017α (17α-hydroxylase/C17-20 lyase). Journal of Steroid Biochemistry and Molecular Biology 50(5-6), 267-273 (1994). 2.Potter, G.A.,Barrie, S.E.,Jarman, M., et al. Novel steroidal inhibitors of human cytochrome P45017α (17α-hydroxylase-C17,20-lyase): Potential agents for the treatment of prostatic cancer. Journal of Medicinal Chemistry 38(13), 2463-2471 (1995). 3.ODonnell, A.,Judson, I.,Dowsett, M., et al. Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. British Journal of Cancer 90(12), 2317-2325 (2004). 4.Ryan, C.J.,Smith, M.R.,de Bono, J.S., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. New England Journal of Medicine 368(2), 138-148 (2013). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 349.5 |
| 分子式 | C24H31NO |
| CAS号 | 154229-19-3 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |